ATS 2024: Late-Breaking Abstract on Rademikibart Phase 2b Asthma Trial

Connect Biopharma is a clinical-stage biopharmaceutical company that is dedicated to advancing the treatment of chronic inflammatory diseases. The company's mission is to enhance the quality of life for patients by connecting them with innovative therapeutic solutions. Their focus is on developing next-generation treatments for T cell-driven inflammatory diseases, which are conditions where the immune system's T cells contribute to inflammation.

One of the company's key products in development is CBP-201, an antibody that targets the interleukin-4 receptor alpha (IL-4Rα). This drug is currently undergoing clinical trials for the treatment of atopic dermatitis (AD), a chronic skin condition characterized by itchy rashes. The Phase 2b study of CBP-201 demonstrated significant improvement in patients with moderate-to-severe AD, as measured by the reduction in eczema area and severity index (EASI) at week 16. The drug has also shown promise in treating moderate-to-severe persistent asthma with type 2 inflammation.

Another product candidate from Connect Biopharma is CBP-307, a small molecule modulator of S1P1 receptors. This compound is being evaluated in a global Phase 2 clinical study for patients with ulcerative colitis, a type of inflammatory bowel disease. Unlike pro-drugs, CBP-307 does not require conversion to an active form after administration, which may offer a therapeutic advantage.

Additionally, the company is developing CBP-174, a small molecule histamine H3 receptor antagonist for the treatment of chronic pruritus, or itching, associated with skin inflammation. CBP-174 is designed for oral administration and is currently in a Phase 1 dose-escalation study. Early results from preclinical models suggest that CBP-174 could rapidly reduce itching, which is a significant symptom for many patients with skin conditions.

Connect Biopharma's approach to drug discovery is underpinned by a deep understanding of Th2 cell biology. Th2 cells are a subset of T cells that play a crucial role in immune responses but can contribute to inflammation when their activity is abnormal. The company's proprietary Immune Modulation Technology Platform is designed to accelerate the discovery of novel small molecules and biologics with the potential to be best-in-class or first-in-class therapies for serious autoimmune and inflammatory diseases where there is a significant unmet medical need.

The company's commitment to improving patient lives is evident in their ongoing clinical trials and their dedication to addressing unmet medical needs. As they continue to innovate and develop new therapies, Connect Biopharma aims to make a significant impact on the treatment landscape for T cell-driven inflammatory diseases.